{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "OtherID": [], "CitationSubset": [], "InvestigatorList": [], "SpaceFlightMission": [], "GeneralNote": [], "OtherAbstract": [], "PMID": "28879109", "DateRevised": {"Year": "2020", "Month": "10", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2016", "Month": "06", "Day": "09"}], "ELocationID": ["363", "10.4102/ajlm.v5i1.363"], "Language": ["eng"], "Journal": {"ISSN": "2225-2002", "JournalIssue": {"Volume": "5", "Issue": "1", "PubDate": {"Year": "2016"}}, "Title": "African journal of laboratory medicine", "ISOAbbreviation": "Afr J Lab Med"}, "ArticleTitle": "Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: A systematic review with regional discussion.", "Pagination": {"StartPage": "363", "MedlinePgn": "363"}, "Abstract": {"AbstractText": ["Despite vast improvements in transfusion services in sub-Saharan Africa over the last decade, there remain serious concerns on the safety and adequacy of the blood supply across the region.", "This review paper ascertains the role of pathogen reduction technology (PRT) in improving blood safety and supply adequacy in the region.", "The state of blood safety in sub-Saharan Africa was reviewed. Meetings, seminars and correspondence were undertaken with key clinicians, scientists and professional bodies in the region, including the World Health Organization's Regional Office for Africa, to examine the suitability of PRT for improving the safety of whole blood transfusion, a prevalent transfusion format in the region.", "Existing literature suggests that combining PRT with current blood safety measures (such as serology) would improve the safety and adequacy of the blood supply for transfusions in sub-Saharan Africa. This was echoed by the findings of the stakeholder meetings.", "Following a detailed appraisal of two leading PRT systems, the Mirasol<sup>\u00ae</sup> PRT System and the Cerus S-303 System, we suggest that companies conduct comprehensive toxicological evaluation of the agents used for PRT and publish this in the scientific literature. We also recommend that the safety and efficacy of these technologies should be established in a randomised clinical trial conducted in sub-Saharan Africa."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "N-S TechnoMed, London, United Kingdom."}], "LastName": "Nkohkwo", "ForeName": "Asa'ah", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Institute of Medical Research and Medicinal Plants Studies, Yaound\u00e9, Cameroon."}], "LastName": "Agbor", "ForeName": "Gabriel", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical Sciences, Faculty of Health Sciences, University of Buea and Toxicology Society, Buea, Cameroon."}], "LastName": "Asongalem", "ForeName": "Emmanuel", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Haematology and Blood Transfusion Service, University Teaching Hospital, Yaound\u00e9, Cameroon."}], "LastName": "Tagny", "ForeName": "Claude", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Immunology, Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 1, Yaound\u00e9, Cameroon."}], "LastName": "Asonganyi", "ForeName": "Tazoacha", "Initials": "T"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "South Africa", "MedlineTA": "Afr J Lab Med", "NlmUniqueID": "101603205", "ISSNLinking": "2225-2002"}, "CoiStatement": "The authors declare an unconditional financial support from Terumo BCT (manufacturers of the Mirasol PRT system) during this study. The statements made are the independent collective position of the authors on the respective issues discussed."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "World Health Organization \nThe Millennium Development Goals [page on the Internet]. c2000 [cited 2015 May 31]. Available from: http://www.who.int/mediacentre/factsheets/fs290/en/"}, {"Citation": "Bloch EM, Vermeulen M, Murphy E. \nBlood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfus Med Rev. 2012;26(2):164\u2013180. http://dx.doi.org/10.1016/j.tmrv.2011.07.006", "ArticleIdList": ["10.1016/j.tmrv.2011.07.006", "PMC3668661", "21872426"]}, {"Citation": "Tagny CT, Murphy EL, Lefr\u00e8re JJ. \nThe Francophone Africa Blood Transfusion Research Network: a five-year report (2007\u20132012). Transfus Med. 2013;23(6):442\u2013444. http://dx.doi.org/10.1111/tme.12076", "ArticleIdList": ["10.1111/tme.12076", "24003976"]}, {"Citation": "Lefr\u00e8re JJ, Dahourouh H, Dokekias AE, et al. . \nEstimate of the residual risk of transfusion-transmitted human immunodeficiency virus infection in sub-Saharan Africa: a multinational collaborative study. Transfusion. 2011;51(3):486\u2013492. http://dx.doi.org/10.1111/j.1537-2995.2010.02886.x", "ArticleIdList": ["10.1111/j.1537-2995.2010.02886.x", "20880002"]}, {"Citation": "Owusu-Ofori AK, Parry C, Bates I. \nTransfusion-transmitted malaria in countries where malaria is endemic: a review of the literature from sub-Saharan Africa. Clin Infect Dis. 2010;51(10):1192\u20131198. http://dx.doi.org/10.1086/656806", "ArticleIdList": ["10.1086/656806", "20929356"]}, {"Citation": "Burnouf T, Emmanuel J, Mbanya D, et al. . \nEbola: call for blood transfusion safety in sub-Saharan Africa. Lancet. 2014;384(9951):1347\u20131348. http://dx.doi.org/10.1016/S0140-6736(14)61693-7", "ArticleIdList": ["10.1016/S0140-6736(14)61693-7", "25277678"]}, {"Citation": "Olawumi HO, Fadeyi A, Babatunde SK, et al. . \nMalaria parasitaemia among blood donors in Ilorin, Nigeria. Afr J Infect Dis. 2015;9(1):10\u201313. http://dx.doi.org/10.4314/ajid.v9i1.3", "ArticleIdList": ["10.4314/ajid.v9i1.3", "PMC4325353", "25722845"]}, {"Citation": "Tapko J-B, Mainuka P, Diarra-Nama AJ. Status of blood safety in the WHO African region. Report of the 2004 survey. WHO-Afro Brazzaville, Congo; 2006."}, {"Citation": "Tapko J-B, Toure B, Sambo LG. Status of blood safety in the WHO African region. Report of the 2010 survey. WHO-Afro Brazzaville, Congo; 2014."}, {"Citation": "Pitman JP, Wilkinson R, Liu Y, et al. . \nBlood component use in a sub-Saharan African country: results of a 4-year evaluation of diagnoses associated with transfusion orders in Namibia. Transfus Med Rev. 2015;29(1):45\u201351. http://dx.doi.org/10.1016/j.tmrv.2014.11.003", "ArticleIdList": ["10.1016/j.tmrv.2014.11.003", "25573416"]}, {"Citation": "World Health Organization Availability, safety and quality of blood products. Executive Board EB125/5. 125th Session Geneva May 7 WHO; 2009."}, {"Citation": "Asanghanwa CMN. Clinical indications of blood transfusion at the Yaound\u00e9 University Teaching Hospital and the Cit\u00e9 Verte District Hospital. MD Thesis, Department of Microbiology, Haematology and Cancerology, Faculty of Medicine & Biomedical Sciences, University of Yaounde 1, Cameroon; 2013."}, {"Citation": "World Health Organization \nMaking safe blood available in Africa [document on the Internet]. c2014 [cited 2014 Jul 09]. Available from: http://www.who.int/bloodsafety/makingsafebloodavailableinafricastatement.pdf?ua=1"}, {"Citation": "Tapko J-B. Coping with Ebola crisis in transfusion services in West Africa. Presentation to the 25th Regional Congress of the International Society for Blood Transfusion, London, United Kingdom 1 July 2015."}, {"Citation": "Tagny CT, Mbanya D, Tapko J-B, et al. . \nBlood safety in sub-Saharan Africa: a multi-factorial problem. Transfusion. 2008;48(6):1256\u20131261. http://dx.doi.org/10.1111/j.1537-2995.2008.01697.x", "ArticleIdList": ["10.1111/j.1537-2995.2008.01697.x", "18713111"]}, {"Citation": "Balshem H, Heland M, Sch\u00fcnemann HJ, et al. . \nGRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u2013406. http://dx.doi.org/10.1016/j.jclinepi.2010.07.015", "ArticleIdList": ["10.1016/j.jclinepi.2010.07.015", "21208779"]}, {"Citation": "Garson D, Lillvik C. 2012. The literature review: a research journey [pictorial] In: A guide to quality improvement methods. Health Quality Improvement Partnership (HQIP) London, 2015; p. 8."}, {"Citation": "Picker SM. Pathogen reduction technologies: the best solution for safer blood? J Blood Disorders Transf. 2012;3:133."}, {"Citation": "Picker SM. Current methods for the reduction of blood-borne pathogens: a comprehensive literature review. Blood Transfus. 2013;11(3):343\u2013348.", "ArticleIdList": ["PMC3729123", "23522896"]}, {"Citation": "Schlenke P.\nPathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother. 2014;41(4):309\u2013325. http://dx.doi.org/10.1159/000365646", "ArticleIdList": ["10.1159/000365646", "PMC4164100", "25254027"]}, {"Citation": "Nkohkwo A, Talboys N, Ndihokubwayo J-B, et al. . Improving blood supply safety and adequacy in Africa. A meeting at the WHO, Brazzaville, Congo, January 2014 (unpublished report)."}, {"Citation": "Nkohkwo A, Talboys N. Improving blood supply safety and adequacy in developing countries: pan-African blood safety perspectives. Abstract for the 2nd Congress of the African Society for Laboratory Medicine; Nov 30 \u2013 Dec 4 Cape Town, South Africa; 2014."}, {"Citation": "Nkohkwo A, Asonganyi T, Agbor G, et al. . Toxicological aspects of pathogen reduction/inactivation system for use in Cameroon. A roundtable seminar, Hilton. Yaound\u00e9, Cameroon, 29\u201330 January 2015 (unpublished report)."}, {"Citation": "Safe Blood for Africa Foundation Desktop analysis of Blood Safety in Cameroon. Rivonia, South Africa: SFBA, 2013; p23."}, {"Citation": "Konotey-Ahulu FID. The sickle cell disease patient. Tettah-A\u2019Domeno Co. Watford, England; 1996."}, {"Citation": "NHS Sickle cell disease in childhood- standards and guidelines for clinical care. NHS Screening Programmes, London; 2006. & 2010."}, {"Citation": "World Health Organization The management of haemoglobin disorders. Report of Joint WHO\u2013TIF meeting. Nicosia, Cyprus, November 2007. WHO; 2008."}, {"Citation": "Sickle Cell Society Standards for the clinical care of adults with sickle cell disease in the UK. Sickle Cell Society, London; 2008."}, {"Citation": "Mbanya DS. Sickle cell disease in sub-Saharan Africa. Presentation to the 25th Regional Congress of the International Society for Blood Transfusion, London, United Kingdom 1 July 2015."}, {"Citation": "Terumo BCT.\nCaridianBCT receives CE mark for Mirasol\u00ae Pathogen Reduction Technology System [page on the Internet]. c2007 [cited 2016 May 06]. Available from: https://www.terumobct.com/location/north-america/about-terumobct/press-room/Pages/MirasolPathogenReductionTechnologySystemforPlateletsReceivesCEMark.aspx"}, {"Citation": "Cerus Corporation \nIntercept Blood System CE mark [page on the Internet]. n.d. \n[cited 2016 May 06]. Available from: http://www.interceptbloodsystem.com/resource-center/ce-mark-a-iso-certificates"}, {"Citation": "Owusu-Ofori S, Allain JP. AIMS trial: Report of the first randomized control trial with Mirasol-treated whole blood. The findings of an RCT study in Ghana. Presentation to the 25th Regional Congress of the International Society for Blood Transfusion, London, United Kingdom 1 July 2015."}, {"Citation": "Allain JP, Owusu-Ofori S. AIMS Trial: Report of the first randomized control trial with Mirasol-treated whole blood. The findings of an RCT study in Ghana. Presented to the meeting of the American Society of Haematology; 2015. In press."}, {"Citation": "SaBTO (Advisory Committee on the Safety of Blood Tissues & Organs) Donor selection criteria review. Department of Health, London; April 2011."}, {"Citation": "Allain JP.\nMoving on from voluntary non-remunerated donors: who is the best blood donor?\nBr J Haematol. 2010;154(6):763\u2013769. http://dx.doi.org/10.1111/j.1365-2141.2011.08708.x", "ArticleIdList": ["10.1111/j.1365-2141.2011.08708.x", "21539535"]}, {"Citation": "Field SP, Allain JP. \nTransfusion in sub-Saharan Africa: does a Western model fit?\nJ Clin Pathol. 2007;60(10);1073\u20131075. http://dx.doi.org/10.1136/jcp.2006.043505", "ArticleIdList": ["10.1136/jcp.2006.043505", "PMC2014840", "17412874"]}, {"Citation": "Hourfar MK, Jork C, Schottstedt V, et al. . \nExperience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion. 2008;48(8):1558\u20131566. http://dx.doi.org/10.1111/j.1537-2995.2008.01718.x", "ArticleIdList": ["10.1111/j.1537-2995.2008.01718.x", "18466173"]}, {"Citation": "Bihl F, Castelli D, MArincola F, et al. . \nTransfusion-transmitted infections. J Transl Med. 2007;5:25\nhttp://dx.doi.org/10.1186/1479-5876-5-25", "ArticleIdList": ["10.1186/1479-5876-5-25", "PMC1904179", "17553144"]}, {"Citation": "Jayaraman S, Chalabi Z, Perel P, et al. . \nThe risk of transfusion-transmitted infections in sub-Saharan Africa. Transfusion\n2010;50(2);433\u2013442. http://dx.doi.org/10.1111/j.1537-2995.2009.002402.x", "ArticleIdList": ["10.1111/j.1537-2995.2009.002402.x", "19843290"]}, {"Citation": "Mufti N, Erickson A, Pinkoski L, et al. . Whole blood pathogen inactivation to improve blood safety. Poster presented at the Global Maternal Child Health Conference, Arusha, Tanzania, 15\u201317 January 2013."}, {"Citation": "Goodrich RP, Edrich RA, Goodrich LL, et al. . Chapter 5. The antiviral and antibacterial properties of riboflavin and light: applications to blood safety and transfusion medicine In: Silva E, Edwards A (editors), Flavins: Photochemistry & Photobiology. Cambridge: RSC Publishing, 2006; pp. 83\u2013113."}, {"Citation": "Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline Chapter 5: Riboflavin In: Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington (DC): National Academies Press (US), 1998; pp. 87\u2013122.", "ArticleIdList": ["23193625"]}, {"Citation": "Letowska M, Windyga J, Poglod R, et al. . Clinical effect of therapeutic plasma exchange (TPE) with Mirasol PRT-treated fresh frozen plasma in patients with acquired thrombotic thrombocytopenic purpura (TTP). Transfusion. 2013;53(suppl):116A."}, {"Citation": "Picker SM, Steisel A, Gathof BS. \nCell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci. 2009;40(2):79\u201385. http://dx.doi.org/10.1016/j.transci.2009.01.013", "ArticleIdList": ["10.1016/j.transci.2009.01.013", "19233725"]}, {"Citation": "Picker SM, Oustianskaia L, Schneider V, et al. . \nFunctional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang. 2009;97(1):26\u201333. http://dx.doi.org/10.1111/j.1423-0410.2009.01176.x", "ArticleIdList": ["10.1111/j.1423-0410.2009.01176.x", "19302416"]}, {"Citation": "Reddy HL, Dayan AD, Cavagnaro J, et al. . \nToxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev. 2008;22(2):133\u2013153. http://dx.doi.org/10.1016/j.tmrv.2007.12.003", "ArticleIdList": ["10.1016/j.tmrv.2007.12.003", "18353253"]}, {"Citation": "Reddy HL.\nThe Mirasol system for whole blood [document on the Internet]. c2012 [cited 2015 Jun 18]. Available from: http://rdcr.org/wp-content/uploads/symp2012pdf/The%20mirasol%20system%20for%20whole%20blood%20-%20Heather%20Reddy.pdf"}, {"Citation": "Lin L, Mufti N. Pathogen inactivation of red blood cell concentrates (RBC) and whole blood (WB) using the INTERCEPT\u2122 technology: advances and challenges Presented at the 6th IABS Symposium on Advances in Transfusion Safety. Queens\u2019 College, Cambridge, UK: 6 July 2009."}, {"Citation": "Stassinopoulos A, Pinkoski L, Postich M, et al. . Frangible anchor linker effector compounds structure optimization for pathogen inactivation in whole blood Poster presented at the 32nd Congress of the International Society of Blood Transfusion, Cancun, Mexico, 7\u201312 July 2012."}, {"Citation": "Henschler R, Seifried E, Mufti N. \nDevelopment of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother. 2011;38(1):33\u201342. http://dx.doi.org/10.1159/000324458", "ArticleIdList": ["10.1159/000324458", "PMC3132978", "21779204"]}, {"Citation": "North A, Ciaravino V, Mufti N, et al. . \nPreclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion. 2011;51(10):2208\u20132218. http://dx.doi.org/10.1111/j.1537-2995.2011.03132.x", "ArticleIdList": ["10.1111/j.1537-2995.2011.03132.x", "21985050"]}, {"Citation": "Cook D, Merritt JE, Nerio A, et al. . Frangible compounds for pathogen inactivation. Patent No. US6093725 A, July 25, 2000."}, {"Citation": "Ehsanian R, Van Waes C, Feller SM. \nBeyond DNA binding \u2013 a review of the potential mechanisms mediating quinacrine\u2019s therapeutic activities in parasitic infections, inflammation, and cancers. J Cell Commun Signal. 2011;9:13\nhttp://dx.doi.org/10.1186/1478-811X-9-13", "ArticleIdList": ["10.1186/1478-811X-9-13", "PMC3117821", "21569639"]}, {"Citation": "Shannon JA, Earle DP, Brodie BB, et al. . The pharmacological basis for the rational use of Atabrine in the treatment of malaria. J Pharmacol Exp Ther. 1944;81(4):307\u2013330."}, {"Citation": "Goodman LS, Gilman A, (Eds.), Goodman and Gilman\u2019s The pharmacological basis of therapeutics. New York: Macmillian; 1955."}, {"Citation": "US Army \nPlasma quinacrine concentration as a function of dosage and environment. Arch Intern Med (Chic). 1946;78:64\u2013107. http://dx.doi.org/10.1001/archinte.1946.00220010074007", "ArticleIdList": ["10.1001/archinte.1946.00220010074007", "20994320"]}, {"Citation": "Wallace DJ.\nThe use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum. 1989;18(4):282\u2013296. http://dx.doi.org/10.1016/0049-0172(89)90050-4", "ArticleIdList": ["10.1016/0049-0172(89)90050-4", "2658071"]}, {"Citation": "Looareesuwan S, Phillips RE, Edwards G, et al. . Mepacrine accumulation during treatment of chloroquine-resistant falciparum malaria. Ann Trop Med Parasitol. 1988;82(2):107\u2013112.", "ArticleIdList": ["3052330"]}, {"Citation": "Thomas G. Chapter 4: The SAR and QSAR approach to drug design In: Thomas G (editor), Fundamentals of medicinal chemistry. London: John Wiley & Sons Ltd., 2003; pp. 71\u201394."}, {"Citation": "Dashwood RH, Yamane S, Larsen R. \nStudy of the forces of stabilizing complexes between chlorophylls and heterocyclic amine mutagens. Environ Mol Mutagen. 1996;27(3):211\u2013218. http://dx.doi.org/10.1002/(SICI)1098-2280(1996)27:3<211::AID-EM6>3.0.CO;2-H", "ArticleIdList": ["10.1002/(SICI)1098-2280(1996)27:3<211::AID-EM6>3.0.CO;2-H", "8625957"]}, {"Citation": "Pietrzak M, Wieczorek Z, Stachelska A, et al. . \nInteractions of chlorophyllin with acridine orange, quinacrine mustard and doxorubicin analyzed by light absorption and fluorescence spectroscopy. Biophys Chem. 2003;104(1):305\u2013313. http://dx.doi.org/10.1016/S0301-4622(02)00387-3", "ArticleIdList": ["10.1016/S0301-4622(02)00387-3", "PMC3480723", "12834849"]}, {"Citation": "Laikind PK, Allison WS. Quinacrine mustard inactivates the bovine heart mitochondrial F1-ATPase with the modification of the \u03b2-subunit. J. Biol Biochem. 1983;258(19):11700\u201311704.", "ArticleIdList": ["6225779"]}, {"Citation": "Yu Y, Shi L, Karlin A. \nStructural effects of quinacrine binding in the open channel of the acetylcholine receptor. PNAS. 100(7):3907\u20133912. http://dx.doi.org/10.1073/pnas.0730718100", "ArticleIdList": ["10.1073/pnas.0730718100", "PMC153021", "12644710"]}, {"Citation": "Greenberg M, Tsong TY. Detergent solubilization and affinity purification of a local anesthetic binding protein from mammalian axonal membranes. J. Biol Chem. 1984;259(21):13241\u201313245.", "ArticleIdList": ["6490653"]}, {"Citation": "Ardelt B, Kunicki J, Traganos F, et al. . Chlorphyllin protects cells from the cytostatic and cytotoxic effects of quinacrine mustard but not of nitrogen mustard. Int J Oncol. 2001;18(4):849\u2013853.", "ArticleIdList": ["11251184"]}, {"Citation": "Tagny CT, El Dusouqui S, Rigal E, et al. . Whole blood pathogen reduction: which benefit for blood safety in Africa? Int J Hematol Res. 2015;1(1):27\u201328."}], "ReferenceList": []}], "History": [{"Year": "2015", "Month": "9", "Day": "12"}, {"Year": "2016", "Month": "3", "Day": "1"}, {"Year": "2017", "Month": "9", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "6", "Day": "9", "Hour": "0", "Minute": "0"}, {"Year": "2016", "Month": "6", "Day": "9", "Hour": "0", "Minute": "1"}, {"Year": "2016", "Month": "6", "Day": "9"}], "PublicationStatus": "epublish", "ArticleIdList": ["28879109", "PMC5436399", "10.4102/ajlm.v5i1.363", "AJLM-5-363"]}}], "PubmedBookArticle": []}